Quantcast
Home > Quotes > NTLA
NTLA

Intellia Therapeutics, Inc. Common Stock (NTLA) Quote & Summary Data

$28.97
*  
0.02
0.07%
Get NTLA Alerts
*Delayed - data as of Jun. 19, 2018  -  Find a broker to begin trading NTLA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    NTLA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 28.98 / $ 27.25
Share Volume
1,156,586
50 Day Avg. Daily Volume
914,280
Previous Close
$ 28.95
52 Week High / Low
$ 35.99 / $ 12.43
Market Cap
1,248,311,796
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,156,586
50 Day Avg. Daily Volume:
914,280

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.01

Trading Range

The current last sale of $28.97 is 133.07% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 28.98 $ 35.99
 Low: $ 27.25 $ 12.43

Company Description (as filed with the SEC)

We are a leading genome editing company focused on the development of proprietary, curative therapeutics utilizing a biological tool known as CRISPR/Cas9. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes or genetic material in the human body with a single treatment course, and via cell therapies that can replace a patient's diseased cells or better target cancer and immunological diseases using engineered immune cells. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property (IP) position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new class of therapeutic products. In 2012, one of our co-founders and current scientific advisors, Dr. Jennifer Doudna, and her colleagues published a paper in the journal Science describing the use of CRISPR/Cas9 as a genome editing tool.  ... More ...  

Risk Grade

Where does NTLA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 28.40
Open Date:
Jun. 19, 2018
Close Price:
$ 28.95
Close Date:
Jun. 19, 2018

Consensus Recommendation

Analyst Info